Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Meeting ReportOncology: Basic, Translational & Therapy: Basic Science

Preclinical evaluation of TSPO ligand [18F]DPA-714 for PET imaging of glioma

Dewei Tang, Eliot McKinley, Matthew Hight, Allie Fu, Jason Buck, R. Smith, Mike Nickels, Mohammed Ansari, Mohammed Tantawy and H. Charles Manning
Journal of Nuclear Medicine May 2011, 52 (supplement 1) 193;
Dewei Tang
1Vanderbilt University, Nashville, TN
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Eliot McKinley
1Vanderbilt University, Nashville, TN
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Matthew Hight
1Vanderbilt University, Nashville, TN
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Allie Fu
1Vanderbilt University, Nashville, TN
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jason Buck
1Vanderbilt University, Nashville, TN
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
R. Smith
1Vanderbilt University, Nashville, TN
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mike Nickels
1Vanderbilt University, Nashville, TN
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mohammed Ansari
1Vanderbilt University, Nashville, TN
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mohammed Tantawy
1Vanderbilt University, Nashville, TN
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
H. Charles Manning
1Vanderbilt University, Nashville, TN
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
Loading

Abstract

193

Objectives Translocator protein (TSPO) is a crucial trans-mitochondrial membrane protein involved in numerous cellular functions that include cholesterol metabolism, steroidogenesis, and apoptosis. Elevated TSPO expression is found in numerous diseases, ranging from neuroinflammation to cancer. We recently reported successful use of the aryloxyanilide [18F]PBR06 for preclinical imaging of glioma. Building upon these studies, we have evaluated the high-affinity pyrazolopyrimidine-based TSPO ligand, [18F]DPA-714, to quantitatively assess TSPO expression in a preclinical model of glioma.

Methods [18F]DPA-714 was synthesized in high specific activity using published methods. Wistar rats were stereotactically inoculated in the right hemisphere with tumor cells (C6 glioma) or vehicle. Rats were imaged in a microPET system. A 90 min dynamic acquisition was started simultaneously with injection of [18F]DPA-714. Arterial blood was collected to derive the arterial input function (AIF) and HPLC radiometabolite analysis performed on select blood samples. Compartmental modeling of the PET data was performed using a corrected AIF and PMOD program.

Results [18F]DPA-714 preferentially accumulated in tumor with little uptake in healthy brain, facilitating excellent contrast between tumor and normal tissue. Time-activity curves from tumor and healthy brain regions could be fit to a 3-compartment, 4-parameter model. Infusion with cold ligand displaced tracer binding approximately 90%. Accumulation of [18F]DPA-714 in tumor and adjacent brain agreed with ex vivo assay of TSPO protein levels by Western blot and quantitative IHC.

Conclusions These data illustrate [18F]DPA-714 as a promising tracer for visualization of TSPO-expressing tumors, with uptake accurately reflecting TSPO densities in normal brain and tumor tissue. Accordingly, [18F]DPA-714 appears to be an ideal candidate probe for exploration of TSPO expression in other preclinical cancer models with future applications in human cancer imaging studies

Back to top

In this issue

Journal of Nuclear Medicine
Vol. 52, Issue supplement 1
May 2011
  • Table of Contents
  • Index by author
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Preclinical evaluation of TSPO ligand [18F]DPA-714 for PET imaging of glioma
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Preclinical evaluation of TSPO ligand [18F]DPA-714 for PET imaging of glioma
Dewei Tang, Eliot McKinley, Matthew Hight, Allie Fu, Jason Buck, R. Smith, Mike Nickels, Mohammed Ansari, Mohammed Tantawy, H. Charles Manning
Journal of Nuclear Medicine May 2011, 52 (supplement 1) 193;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Preclinical evaluation of TSPO ligand [18F]DPA-714 for PET imaging of glioma
Dewei Tang, Eliot McKinley, Matthew Hight, Allie Fu, Jason Buck, R. Smith, Mike Nickels, Mohammed Ansari, Mohammed Tantawy, H. Charles Manning
Journal of Nuclear Medicine May 2011, 52 (supplement 1) 193;
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Info & Metrics

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

Oncology: Basic, Translational & Therapy: Basic Science

  • Modification of chemical structure to improve biodistribution of a radiolabeled sigma ligand for tumor-imaging
  • A Cy5** labelled anti-EGFR affibody selectively targets EGFR in mouse xenograft model
  • Time-dependent analysis of 18F-FLT distribution in rat mammary tumors
Show more Oncology: Basic, Translational & Therapy: Basic Science

Basic Science II (Oncology): Peptides/Small Molecules

  • Radiopeptide antagonists for imaging and therapy of GRPR+ tumors
  • GPER-targeted 99mTc-labeled non-steroidal analogues for breast and endometrial cancer imaging demonstrate in vivo estrogen binding of GPER
Show more Basic Science II (Oncology): Peptides/Small Molecules

Similar Articles

SNMMI

© 2025 SNMMI

Powered by HighWire